These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24685546)

  • 41. DNA Topoisomerases as Targets for Antibacterial Agents.
    Hiasa H
    Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
    Kokot M; Anderluh M; Hrast M; Minovski N
    J Med Chem; 2022 May; 65(9):6431-6440. PubMed ID: 35503563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New inhibitors of bacterial topoisomerase GyrA/ParC subunits.
    Black MT; Coleman K
    Curr Opin Investig Drugs; 2009 Aug; 10(8):804-10. PubMed ID: 19649925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methods to assay inhibitors of DNA gyrase and topoisomerase IV activities.
    Fisher LM; Pan XS
    Methods Mol Med; 2008; 142():11-23. PubMed ID: 18437302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis, and antibacterial activity of novel 4,5-dihydro-1H-pyrazole derivatives as DNA gyrase inhibitors.
    Liu JJ; Sun J; Fang YB; Yang YA; Jiao RH; Zhu HL
    Org Biomol Chem; 2014 Feb; 12(6):998-1008. PubMed ID: 24382549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase.
    Sawa R; Takahashi Y; Hashizume H; Sasaki K; Ishizaki Y; Umekita M; Hatano M; Abe H; Watanabe T; Kinoshita N; Homma Y; Hayashi C; Inoue K; Ohba S; Masuda T; Arakawa M; Kobayashi Y; Hamada M; Igarashi M; Adachi H; Nishimura Y; Akamatsu Y
    Chemistry; 2012 Dec; 18(49):15772-81. PubMed ID: 23129443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
    Basarab GS; Manchester JI; Bist S; Boriack-Sjodin PA; Dangel B; Illingworth R; Sherer BA; Sriram S; Uria-Nickelsen M; Eakin AE
    J Med Chem; 2013 Nov; 56(21):8712-35. PubMed ID: 24098982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of
    Roszkowski P; Szymańska-Majchrzak J; Koliński M; Kmiecik S; Wrzosek M; Struga M; Szulczyk D
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008805
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel coumarin-thiazolyl ester derivatives as potential DNA gyrase Inhibitors: Design, synthesis, and antibacterial activity.
    Liu H; Xia DG; Chu ZW; Hu R; Cheng X; Lv XH
    Bioorg Chem; 2020 Jul; 100():103907. PubMed ID: 32413631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and radiosterilization of new hydrazono-quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study.
    Ammar YA; Micky JA; Aboul-Magd DS; Abd El-Hafez SMA; Hessein SA; Ali AM; Ragab A
    Chem Biol Drug Des; 2023 Feb; 101(2):245-270. PubMed ID: 36305722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective.
    Ponnusamy T; Alagumuthu M; Thamaraiselvi S
    Bioorg Med Chem; 2018 Jul; 26(12):3438-3452. PubMed ID: 29803359
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diminishing hERG inhibitory activity of aminopiperidine-naphthyridine linked NBTI antibacterials by structural and physicochemical optimizations.
    Kokot M; Weiss M; Zdovc I; Anderluh M; Hrast M; Minovski N
    Bioorg Chem; 2022 Nov; 128():106087. PubMed ID: 35970069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode.
    Lu J; Patel S; Sharma N; Soisson SM; Kishii R; Takei M; Fukuda Y; Lumb KJ; Singh SB
    ACS Chem Biol; 2014 Sep; 9(9):2023-31. PubMed ID: 24992706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Actions of a Novel Bacterial Topoisomerase Inhibitor against
    Dauda SE; Collins JA; Byl JAW; Lu Y; Yalowich JC; Mitton-Fry MJ; Osheroff N
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of novel oxoindolin derivatives as atypical dual inhibitors for DNA Gyrase and FabH.
    Yang YS; Su MM; Xu JF; Liu QX; Bai LF; Hu XW; Zhu HL
    Bioorg Chem; 2019 Dec; 93():103309. PubMed ID: 31585266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flavone-based analogues inspired by the natural product simocyclinone D8 as DNA gyrase inhibitors.
    Verghese J; Nguyen T; Oppegard LM; Seivert LM; Hiasa H; Ellis KC
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5874-7. PubMed ID: 24060488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Docking and 3D QSAR Studies on Substituted Cyclobutylphenyl Quinoline Derivatives as Inhibitors of Bacterial DNA Gyrase.
    Wani RR; Chaudhari HK
    Curr Comput Aided Drug Des; 2018; 14(4):322-337. PubMed ID: 29766821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
    Ho SY; Wang W; Ng FM; Wong YX; Poh ZY; Tan SWE; Ang SH; Liew SS; Joyner Wong YS; Tan Y; Poulsen A; Pendharkar V; Sangthongpitag K; Manchester J; Basarab G; Hill J; Keller TH; Cherian J
    Eur J Med Chem; 2018 Sep; 157():610-621. PubMed ID: 30125722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.
    Ehmann DE; Lahiri SD
    Curr Opin Pharmacol; 2014 Oct; 18():76-83. PubMed ID: 25271174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New 1,2,4-oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity.
    Frejat FOA; Cao Y; Wang L; Zhai H; Abdelazeem AH; Gomaa HAM; Youssif BGM; Wu C
    Arch Pharm (Weinheim); 2022 Jul; 355(7):e2100516. PubMed ID: 35363388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.